natgillin/translations-raw huggingface dataset:
The largest study IMP24011 (n=793) included patients (n=526) who were not controlled by, contraindicated to, or intolerant to two or more systemic therapies as judged from the patients' histories of psoriasis treatment.
Največja študija IMP24011 (n=793) je vključevala bolnike (n=526), ki niso bili pod nadzorom z, niso imeli kontraindikacij za ali niso prenašali dveh ali več sistemskih zdravil, po presoji podatkov o bolnikovem zdravljenju psoriaze v preteklosti.
Antibody response to an experimental neo-antigen (∅X174) was reduced during Raptiva therapy, but began to normalize 6 weeks after discontinuation of Raptiva therapy and did not demonstrate tolerance induction.
Med zdravljenjem z Raptivo se je zmanjšal odziv protiteles na eksperimentalni neo-antigen (∅X174), vendar se je začel normalizirati 6 tednov po prekinitvi zdravljenja z Raptivo brez znakov razvoja tolerance.
Symptoms that might indicate that you have an infection are fever, wounds, feeling tired, dental problems, a bad cough that lasts longer than 2 weeks, pain in the chest or coughing up blood or sputum.
Znaki, ki lahko kažejo, da imate okužbo so zvišana telesna temperatura, rane, občutek utrujenosti, težave z zobmi, hud prehlad, ki traja dlje kot 2 tedna, bolečine v prsnem košu ali izkašljevanje krvi ali sputuma.
It has the potential to increase the risk or the severity of infections, e.g. tuberculous pneumonia, and reactivate latent, chronic infections e.g. JC virus infection.
Poveča lahko tveganje za okužbe ali za resnost okužbe, na primer za tuberkulozno pljučnico in reaktivira latentne, kronične okužbe, na primer JC virusne
Analysis following long-term use in a cohort of 339 patients with moderate to severe psoriasis receiving Raptiva 1 mg/kg/week, of which 166 patients have been treated for more than 2 years and up to 3 years, did not show any noteworthy differences in frequency of adverse events as compared to 12 weeks of exposure to Raptiva.
Analiza dolgotrajne uporabe v kohortni skupini 339 bolnikov z zmerno do hudo psoriazo, ki so prejemali Raptivo v odmerku 1 mg/kg/teden, od katerih se je 166 bolnikov zdravilo najmanj 2 leti in do 3 let, ni pokazala nobenih omembe vrednih razlik v pogostnosti neželenih dogodkov v primerjavi z 12 tedensko izpostavljenostjo Raptivi.
These symptoms diminished thereafter to a percentage comparable to that of patients treated with placebo.
V nadaljevanju so se ti simptomi zmanjšali na delež, ki je primerljiv z deležem pri bolnikih, ki so prejemali placebo.
Overall less than 1% of patients discontinued therapy because of acute flu-like symptoms.
Skupno je manj kot 1 % bolnikov prekinil zdravljenje zaradi gripi podobnih
This will expose a plastic spiked end that you will use to pierce the vial.
Pokazala se bo plastična konica, s katero prebodete
If blood comes into the syringe, the needle has entered a blood vessel.
Če se v injekcijski brizgi pojavi kri, je igla prodrla v krvno žilo.
There is no known antidote to Raptiva or any specific treatment for Raptiva overdose other than withholding treatment and patient observation.
Ni znanega antidota za Raptivo ali specifičnega zdravljenja prevelikega odmerjanja Raptive, razen ukinitve terapije in opazovanja bolnika.
Long-term exposure:
Dolgotrajna izpostavljenost
c) Malignancies and lymphoproliferative disorders
c) Maligne in limfoproliferativne bolezni
Wipe the top of the vial with an alcohol swab.
Obrišite vrh viale z alkoholno blazinico.
In a clinical study, where subjects were exposed to higher doses of efalizumab (up to 10 mg/kg intravenous), one subject receiving 3 mg/kg intravenous dose experienced hypertension, chills, and fever on the day of study drug dosing, which required hospitalization.
V klinični študiji, kjer so bili posamezniki izpostavljeni višjim odmerkom efalizumaba (do 10 mg/kg intravensko), je ena oseba, ki je prejela 3 mg/kg intravensko, doživela hipertenzijo, mrazenje in vročino na dan odmerjanja preizkušanega zdravila, kar je zahtevalo hospitalizacijo.
Among 3291 patients in the combined safety database, 39 patients presented an erythrodermic or pustular psoriasis (1.2%).
Med 3.291 bolniki v skupni podatkovni bazi, je 39 bolnikov razvilo eritrodermično ali pustulozno psoriazo (1,2 %).
In this small number of patients no differences were observed in pharmacokinetics, pharmacodynamics, clinically noteworthy adverse events or clinical efficacy.
Pri tem majhnem številu bolnikov niso opazili nobenih razlik v farmakokinetiki, farmakodinamiki, kliničnih omembe vrednih neželenih dogodkih ali klinični učinkovitosti.
Therapy should be continued only when adequate response is observed.
Zdravljenje se lahko nadaljuje samo, če je viden zadosten odziv.
There was no evidence of an increased risk of any particular malignancy over time with the exception of non-melanoma skin cancer (0.3 vs. 0.9 per 100 patient-years, short term and long term treatment,
Ni bilo dokazov, da se sčasoma poveča tveganje za katerokoli določeno vrsto malignosti, z izjemo nemelanomskega kožnega raka (0,3 proti 0,9 na 100 bolnikov-let, pri kratkotrajnem oziroma dolgotrajnem zdravljenju) (glejte poglavje 4.4).
Interstitial pneumonitis*
Intersticijska pljučnica*
If you develop a new infection or notice any new or sudden change in thinking, balance, strength, talking, walking or vision, please contact your doctor.
Če razvijete novo okužbo ali opazite novo ali nenadno spremembo mišljenja, ravnotežja, moči, govora, hoje ali vida, se prosimo posvetujte z zdravnikom.
Raptiva is a selective immunosuppressor that alters T-lymphocyte function and may affect host defences against infections.
Raptiva je selektivni zaviralec imunske odzivnosti, ki spremeni delovanje limfocitov T in lahko prizadene obrambo gostitelja proti okužbam.
- If you discontinue Raptiva treatment (and this applies especially to patients not responding to treatment) your psoriasis may significantly worsen.
- Če prekinete zdravljenje z Raptivo (in to še posebej velja za bolnike, ki se ne odzivajo na zdravljenje), se lahko vaša psoriaza pomembno poslabša.
HOW TO USE RAPTIVA
KAKO UPORABLJATI ZDRAVILO RAPTIVA
The elimination half-life was about 5.5-10.5 days at 1 mg/kg/ week subcutaneous.
Razpolovni čas izločanja je bil približno 5,5-10,5 dni pri odmerku 1 mg/kg/teden subkutano.
The dosage and administration schedule in the elderly should be the same as for adults (see also section 4.4).
Uporaba pri starejših (≥ 65 let) Odmerjanje in shema dajanja pri starejših morata biti enaka kot za odrasle (glejte tudi poglavje 4.4).
After 35 days of treatment with Raptiva, the proportion of subjects treated with efalizumab with positive skin test reactions to Candida was significantly reduced compared with the placebo group.
Po 35 dneh zdravljenja z Raptivo, je bil delež bolnikov, ki so prejemali efalizumab s pozitivno kožno reakcijo na Candido pomembno zmanjšan v primerjavi s placebo skupino.
• Immediately inject the solution as follows: Firmly pinch the skin together and insert the needle at a 45° to 90° angle using a dart-like motion.
• Takoj injicirajte raztopino, kot je opisano: trdno stisnite kožo skupaj in z gibom podobnim metu sulice, zabodite iglo pod kotom 45° do 90°.
In case of recurrence or exacerbation of disease, as well as in patients who discontinue Raptiva and are non-responders, the treating physician should institute the most appropriate psoriasis treatment as necessary.
V primeru rekurence ali izbruha bolezni, kakor tudi pri bolnikih, ki so prekinili zdravljenje z Raptivo in so neodzivni, mora lečeči zdravnik po potrebi uvesti najbolj primerno zdravljenje psoriaze.
It is produced by genetically engineered mammalian cells.
Proizvajajo ga genetsko spremenjene celice sesalcev.
* The efalizumab used in the study is the Genentech manufactured product
* Izdelovalec v študiji uporabljenega efalizumaba je Genentech.
Excipients: 2.5 mg polysorbate 20, 3.55 mg histidine, 5.70 mg histidine hydrochloride monohydrate,
Pomožne snovi: 2,5 mg polisorbata 20, 3,55 mg histidina, 5,70 mg histidinijevega klorida
It is recommended to discontinue Raptiva if arthritis occurs during treatment.
Priporočljivo je prekiniti zdravljenje z Raptivo, če se med zdravljenjem pojavi artritis.
All occurrences were asymptomatic and values above 2.5 fold ULN were not more frequent in the Raptiva group than in the placebo group.
Vsi pojavi so bili asimptomatski in vrednosti nad 2,5 kratno ULN niso bile bolj pogoste v skupini bolnikov z Raptivo kot v skupini bolnikov s placebom.
Raptiva acts on the immune system, which may potentially increase your risk of infectious diseases or may reactivate old infections.
Zdravilo Raptiva deluje na imunski sistem, kar lahko potencialno poveča vaše tveganje za okužbe ali lahko reaktivira stare
Increased absolute counts were apparent within 24 hours of the first dose, remained elevated with weekly dosing, and returned to baseline after treatment cessation.
Povečanje absolutnega števila je bilo vidno v 24 urah po prvem odmerku in je ostalo povečano s tedenskimi odmerki ter se je povrnilo na izhodiščno vrednost po prekinitvi zdravljenja.
Raptiva has not been studied in patients with renal or hepatic impairment and should therefore be used with caution in such patients.
Raptive niso preiskušali pri bolnikih z okvaro ledvic ali jeter in je zato potrebna previdnost pri uporabi pri teh bolnikih.
Other therapies that alter T-lymphocyte function have been associated with increased risk of developing serious infections.
Zdravljenje z drugimi zdravili, ki spremenijo delovanje limfocitov T je bilo povezano s povečanim tveganjem za razvoj hudih okužb.
Inhibitory effects were observed on the humoral and T-cell dependent immune responses.
Inhibitorne učinke so opazili na humoralni in od T- celic odvisni imunski odziv.
Symptoms of an allergic reaction are common and generally include overall body itching, hives, skin flushing or rash.
Simptomi alergijske reakcije so pogosti in na splošno vključujejo srbenje celega telesa, urtikarijo, rdečico kože ali izpuščaj.
The vial of powder is designed to be reconstituted (mixed) with the solvent.
Vialo s praškom je treba rekonstituirati (pomešati) z vehiklom.
Discontinuation of treatment may cause a recurrence or exacerbation of plaque psoriasis including erythrodermic and pustular psoriasis, especially in patients not responding to treatment.
Prekinitev zdravljenja lahko povzroči rekurenco ali izbruh plaque psoriaze, vključno z eritrodermično in pustulozno psoriazo, zlasti pri bolnikih, ki se ne odzivajo na zdravljenje.
Efalizumab is a recombinant humanized monoclonal antibody produced in genetically engineered Chinese Hamster Ovary (CHO) cells.
Efalizumab je rekombinantno humanizirano monoklonalno protitelo, izdelano z uporabo genetsko spremenjenih celic kitajskega hrčka (CHO).
- If your weight changes unexpectedly, please contact your doctor.
- Če se vaša telesna masa nepričakovano spremeni, se prosimo posvetujte z zdravnikom.
Efalizumab reduces inflammation of the psoriatic lesions which results in improvement of the affected areas of the skin.
Efalizumab zmanjšuje vnetje psoriaznih lezij, kar se kaže v izboljšanju prizadetih predelov kože.
As with any recombinant product, Raptiva is potentially immunogenic.
Kot vsa rekombinantna zdravila je tudi Raptiva potencialno imunogena.
The effect of renal or hepatic impairment on the pharmacokinetics of efalizumab has not been studied.
Vpliva ledvičnih ali jetrnih okvar na farmakokinetiko efalizumaba niso proučevali.
• Wipe the chosen area with an alcohol swab.
• Obrišite izbrano mesto z alkoholno blazinico.
In general, immunoglobulins are known to cross the placental barrier.
Na splošno je znano, da imunoglobulini prehajajo skozi placento.
Do not shake (Shaking will cause foaming of the Raptiva solution).
Ne stresajte (Stresanje povzroči penjenje raztopine z Raptivo).
Measurements of volume of distribution of the central compartment after single intravenous doses were 110 ml/kg at dose 0.03 mg/kg and 58 ml/kg at dose 10 mg/kg.
Izmerjena volumna porazdelitve v centralnem kompartimentu po enkratnem intravenskem odmerku sta bila 110 ml/kg pri odmerku 0,03 mg/kg in 58 ml/kg pri odmerku 10 mg/kg.
Like all medicines, Raptiva can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Raptiva neželene učinke, ki pa se ne pojavijo pri vseh
Management of patients discontinuing Raptiva includes close observation.
Vodenje bolnikov ob prekinitvi zdravljenja z Raptivo vključuje skrbno spremljanje bolnikov.
• Each pre-filled syringe of solvent contains sufficient water for injections to make up the solution
• Vsaka napolnjena injekcijska brizga z vehiklom vsebuje zadostno količino vode za injekcije za
At the 1 mg/kg/wk dose level (with an initial dose of 0.7 mg/kg the first week), mean efalizumab plasma trough values were 11.1±7.9 µg/ml.
Pri odmerku 1 mg/kg/teden (z začetnim odmerkom 0,7 mg/kg prvi teden), so bile povprečne vrednosti efalizumaba v plazmi 11,1 ± 7,9 µg/ml.
In one patient, thrombocytopenia occurred 3 weeks after treatment discontinuation.
Pri enem bolniku je nastopila trombocitopenija 3 tedne po prekinitvi zdravljenja.
The efficacy of Raptiva versus other systemic therapies in patients with moderate to severe psoriasis has not been evaluated in studies directly comparing Raptiva with other systemic therapies.
Učinkovitost Raptive v primerjavi z drugimi sistemskimi zdravili, pri bolnikih z zmerno do hudo psoriazo, ni bila ovrednotena v študijah z direktno primerjavo Raptive z drugimi sistemskimi zdravili.
The metabolism of efalizumab is through internalisation followed by intracellular degradation as a consequence of either binding to cell surface CD11a or through endocytosis.
Presnovi efalizumaba preko internalizacije sledi intracelularna razgradnja kot posledica bodisi vezave na celično površino CD11a ali preko endocitoze.
Raptiva is a systemic psoriasis medicine.
Raptiva je sistemsko zdravilo za psoriazo.
The present results of Raptiva versus placebo over 12 weeks of treatment with different populations indicate a PASI 75 response to Raptiva in 22% to 39% of patients (see Table 2).
Dosedanji rezultati zdravljenja z Raptivo v primerjavi s placebom v 12 tedenskem zdravljenju različnih populacij, kažejo na PASI 75 odziv na Raptivo, pri 22 % do 39 % bolnikov (glejte tabelo 2).
In pups of mice treated with an antibody analogue of efalizumab, a decrease in T-cell dependent immunity was observed up to at least 11 weeks of age.
Pri mišjih mladičkih, ki so jih zdravili z analogom protitelesa efalizumabu, so opazili zmanjšanje od T celic odvisnega imunskega odziva do najmanj 11 tedna starosti.
An initial single dose of 0.7 mg/kg body weight is given followed by weekly injections of 1.0 mg/kg body weight (maximum single dose should not exceed a total of 200 mg).
Enkratni začetni odmerek je 0,7 mg/kg telesne mase, nato sledi enkrat tedensko dajanje injekcij po 1,0 mg/kg telesne mase (maksimalni enkratni odmerek ne sme preseči skupno 200 mg).
No other medicines should be added to the solution containing Raptiva and Raptiva should not be reconstituted
Nobenih drugih zdravil ne smete dodajati v raztopino z zdravilom Raptiva in zdravila Raptiva ne smete rekonstituirati
If any doubt exists, further evaluation, including Magnetic Resonance Imaging (MRI) scan preferably with contrast, cerebrospinal fluid (CSF) testing for JC viral DNA and repeat neurological assessment, should be considered.
Če obstaja kakršenkoli dvom, naj zdravnik opravi nadaljnje preiskave, ki vključujejo slikanje z magnetno resonanco (MRI), najbolje s kontrastom, ter preiskavo cerebrospinalne tekočine (CSF) na JC virusno DNA in ponovno nevrološko oceno bolnika.
Cytochrome P450 enzymes as well as conjugation reactions are not involved in the metabolism of
Citokrom P450 encimi in reakcije konjugacije ne sodelujejo pri presnovi efalizumaba.
During treatment with Raptiva, cases of exacerbation of psoriasis, including pustular, erythrodermic, and guttate subtypes, have been observed (see section 4.8).
Med zdravljenjem z Raptivo so opazili primere izbruhov psoriaze, vključno s pustuloznimi, eritrodermičnimi in gutatnimi podtipi (glejte poglavje 4.8).
- If you are going to receive any vaccine, please check with your doctor.
- Če načrtujete cepljenje, se prosimo posvetujte z zdravnikom.
Antibodies to efalizumab were detected in only 6% of patients.
Protitelesa na efalizumab so odkrili samo pri 6 % bolnikov.
If you have any further questions on the use of the product, ask your doctor or pharmacist.
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali s farmacevtom.
LFA-1 is present on activated T lymphocytes, and ICAM-1 is up-regulated on endothelial cells and keratinocytes in psoriasis plaques.
LFA-1 je prisoten na aktiviranih limfocitih T in ICAM-1 je pozitivno reguliran na endotelijskih celicah in keratinocitih in psoriaznem plaku.
- If you have any further questions,ask your doctor or pharmacist.
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.
• Signs of facial paralysis usually on one side of the face (such as weakness of face muscles and dribbling) possibly preceded by pain in the ear area.
- Znake paralize obraznega živca, ki so običajno vidni samo na eni strani obraza (npr. mlahavost obraznih mišic in kapljanje sline iz ust), pred njimi pa se lahko pojavijo bolečine v predelu ušesa.
In studies using an initial dose of 0.7 mg/kg followed by 11 weekly doses of 1.0 mg/kg, efalizumab maximally reduced expression of CD11a on circulating T lymphocytes to approximately 15-30% of pre-dose baseline values and saturated CD11a to <5% of baseline available CD11a binding sites.
V študijah z začetnim odmerkom 0,7 mg/kg, ki mu sledi 11 tedenskih odmerkov 1,0 mg/kg, je efalizumab maksimalno zmanjšal ekspresijo CD11a na cirkulirajočih limfocitih T na približno 15-30 % izhodiščne vrednosti pred odmerkom in saturiranega CD11a na <5 % v izhodišču razpoložljivih CD11a vezavnih mest.
• Notice signs of nerve disorder such as tingling or onset of weakness in legs or arms or new or sudden change in thinking, balance, strength, talking, walking or vision.
- Opazite znake bolezni živčevja kot so mravljinčenje ali pojav šibkosti nog in rok ali novo ali nenadno spremembo mišljenja, ravnotežja, moči, govora, hoje ali vida.
It is possible that efalizumab is excreted in human milk.
Možno je, da se efalizumab izloča v materino mleko.
Adverse events (Preferred Terms) in the overall population studied clinically with Raptiva are listed below by frequency of occurrence and by MedDRA System Organ Class.
Neželeni dogodki (zaželjen termin) v celotni klinično proučevani populaciji z Raptivo so našteti spodaj glede na pogostnost pojavljanja in MedDRA organski sistem.
This restriction of the indication of Raptiva is based on the present efficacy data and limited long-term
Ta omejitev uporabe zdravila Raptiva temelji na dosedaj zbranih podatkih o učinkovitosti in omejenih izkušnjah z dolgotrajno uporabo zdravila Raptiva.
The reconstituted solution should be clear to pale yellow and free of particles.
Pripravljena raztopina mora biti prozorna do bledo rumena in brez delcev.
If PML is suspected, further dosing must be suspended until PML has been excluded.
Če posumite na PML, mora bolnik prenehati z nadaljnjim jemanjem zdravila, dokler ne boste pri njem izključili PML.
• Holding the EasyMIX outer cover, place it on top of the vial, then press down so that the plastic spiked end pierces the rubber stopper on the vial.
• Medtem ko držite zunanji pokrovček adapterja EasyMIX, ga položite na vrh viale, pritisnite navzdol, da plastična konica prebode gumijasti zamašek na viali.
All values were between 1.5 fold and 3 fold the ULN, and returned to baseline levels after therapy discontinuation.
Vse vrednosti so bile med 1,5 kratno in 3 kratno vrednostjo ULN in so se povrnile na izhodiščno vrednost po prekinitvi zdravljenja.
For discontinuation guidance see section 4.4.
Za smernice o prekinitvi zdravljenja glejte poglavje 4.4.
Raptiva should be discontinued if a malignancy develops while the patient is on treatment (see sections 4.3 and 4.8).
Dajanje Raptive je treba prekiniti, če se med zdravljenjem razvije maligno obolenje (glejte poglavji 4.3 in 4.8).
Erythema multiforme*
Multiformni eritem*
As regards serious infections, the overall incidence in both controlled and uncontrolled studies of up to 12 weeks was 2.8 per 100 patient-years for Raptiva-treated patients compared with 1.4 per 100 patient-years for placebo-treated patients.
Kar zadeva resne okužbe, je bila celokupna incidenca, tako v kontroliranih kot v nekontroliranih študijah do 12 tednov, 2,8 na 100 bolnikov-let za skupino bolnikov, ki so prejemali Raptivo v primerjavi z 1,4 na 100 bolnikov-let za skupino bolnikov, ki so prejemali placebo.
Your doctor may wish to monitor you and
Zdravnik vas bo morda želel podrobneje pregledati in vas napotiti
Limited data are available on the effects of vaccination in patients receiving Raptiva.
Podatki o vplivu na cepljenje pri bolnikih, ki so prejemali Raptivo, so omejeni.
Based on available platelet count measurements, the onset of platelet decline was between 8 and 12 weeks after the first dose of Raptiva in 5 patients, but occurred later in the other patients.
Na podlagi razpoložljivih meritev števila trombocitov, je nastopilo zmanjšanje trombocitov med 8 in 12 tednom po prvem odmerku Raptive pri 5 bolnikih in kasneje pri ostalih bolnikih.
Through population pharmacokinetic analysis, weight was found to affect efalizumab clearance.
S farmakokinetično analizo populacij so ugotovili, da telesna masa vpliva na očistek efalizumaba.
Raptiva is not recommended for use in children below age 18 due to a lack of data on safety and efficacy.
Zaradi pomankanja podatkov o varnosti in učinkovitosti uporaba Raptive pri otrocih pod 18 let ni priporočljiva.
• Ensure the EasyMIX adapter is firmly attached to the vial, before removing the outer cover.
• Prepričajte se, da je adapter EasyMIX dobro pričvrščen na vialo, preden odstranite zunanji
In the combined safety database of 3291 Raptiva-treated patients at the time of approval, there were nine occurrences (0.3%) of thrombocytopenia with less than 52,000 cells per μl reported.
V skupni podatkovni bazi 3.291 bolnikov zdravljenih z Raptivo, v času odobritve zdravila, so poročali o 9 pojavih (0,3 %) trombocitopenije s številom trombocitov manjšim od 52.000 v μl.
Raptiva may cause mild to moderate flu-like symptoms including headache, chills, nausea, muscle aches and occasionally fever within 48 hours of an injection of Raptiva.
Zdravilo Raptiva lahko povzroči blage do zmerne gripi podobne simptome vključno z glavobolom, mrzlico, slabostjo, bolečinami v mišicah in občasno zvišano telesno temperaturo v 48 urah po injekciji Raptive.
Take special care with Raptiva: - If you experience hypersensitivity or allergic reactions such as overall body itching, hives, skin flushing or rash tell your doctor immediately or go to the local casualty.
Bodite posebno pozorni pri uporabi zdravila Raptiva: - Če dobite preobčutljivostno ali alergijsko reakcijo, kot je srbenje celega telesa, urtikarijo, pordelost kože ali izpuščaj, takoj obvestite svojega zdravnika ali poiščite najbližjo nujno zdravniško pomoč.
In a study of 66 patients with moderate plaque psoriasis, immune responses during and after Raptiva treatment were investigated.
V študiji s 66 bolniki z zmerno psoriazo s plaki so proučevali vpliv na imunski odziv med in po zdravljenju z Raptivo.
Efalizumab shows dose-dependent nonlinear pharmacokinetics which can be explained by its saturable specific binding to cell surface receptors CD11a.
Efalizumab kaže od odmerka odvisno nelinearno farmakokinetiko, ki jo lahko pojasnimo z nasičenostjo njegove specifične vezave na površinske celične receptorje CD11a.
In clinical trials, visible side effects at the injection site and injection site pain were uncommon.
V kliničnih preskušanjih so bili vidni neželeni učinki na mestu injiciranja in bolečina na mestu injiciranja občasni.
If you are breastfeeding, your doctor will advise you either to discontinue breastfeeding or to discontinue Raptiva while breastfeeding.
Če dojite, vam bo zdravnik svetoval, da bodisi prekinete dojenje ali pa uporabo zdravila Raptiva v obdobju dojenja.